Benjamin Hohl, CFO: Enliven Therapeutics ELVN Sell · Filed 23/12/27

Trade details

Type: Insider sale
Amount: $15,522.1
Shares · price: 1,030 sh · $15.07 a share
Held after: 0 sh
Stock: Enliven Therapeutics ELVN
Person: Benjamin HohlCFO
Trade date: 23/12/22
Filed: 23/12/27
Days to filing: 5 days

Sold 100.0% of holdings

Share of holding sold: 100.0%

Enliven Therapeutics trades, last 26 weeks

What else happened in Enliven Therapeutics around then

Filed or reported within 30 days of the trade day · 23/11/22~24/01/21

Benjamin Hohl's recent trades

Benjamin HohlCFO
Planned sale10b5-1 planEnliven Therapeutics
Planned sale10b5-1 plan
Enliven Therapeutics
ELVN
$591.2K
12,036 sh
$591.2K
Filed 09/17
Traded 09/17
Benjamin HohlCFO
Sell10b5-1 planEnliven Therapeutics
Sell10b5-1 plan
Enliven Therapeutics
ELVN
$149.2K
3,401 sh
$149.2K
Filed 06/22
Traded 06/17
Benjamin HohlCFO
Sell10b5-1 planEnliven Therapeutics
Sell10b5-1 plan
Enliven Therapeutics
ELVN
$59K
1,379 sh
$59K
Filed 06/22
Traded 06/17
Benjamin HohlCFO
Sell10b5-1 planEnliven Therapeutics
Sell10b5-1 plan
Enliven Therapeutics
ELVN
$55.4K
1,238 sh
$55.4K
Filed 06/22
Traded 06/17
Benjamin HohlCFO
Planned sale10b5-1 planEnliven Therapeutics
Planned sale10b5-1 plan
Enliven Therapeutics
ELVN
$768.2K
18,054 sh
$768.2K
Filed 06/17
Traded 06/17

Benjamin Hohl, CFO — sold $15.5K of Enliven Therapeutics ELVN · 100.0% of holdings · 10b5-1 plan | Whalegun